Browse the evidence

Behavioral interventions and pharmacological therapies may be effective strategies for weight management in PWH.

Integrating behavioral and pharmacological approaches may enhance weight management efforts in PWH.

New glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been confirmed to reduce weight and preserve kidney function.

Clinicians may consider these new drugs as effective treatment options for managing ORG.

Addition of glucagon receptor agonism enhances weight loss, reduces liver fat, and ameliorates dyslipidemia.

Practitioners should consider glucagon receptor agonists for their potential benefits in weight loss and metabolic health.

Liraglutide and semaglutide may provide benefits for weight loss and glycaemic control in people living with HIV.

Practitioners may consider liraglutide and semaglutide for weight management in HIV patients, particularly those with diabetes.

The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.

Practitioners should consider semaglutide as a treatment option for improving outcomes in obese HFpEF patients.

GLP-1RA medications are effective in achieving optimal glucose control and reducing all-cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and end-stage kidney disease in individuals with type 1 and type 2 diabetes.

GLP-1RA medications can be considered for improving glucose control and reducing serious health risks in diabetic patients.

NuSH-based therapies, including semaglutide and tirzepatide, are highly effective for the treatment of overweight (BMI >27 kg·m−2 with a health condition) and obesity (BMI >30 kg·m−2), with average weight loss exceeding that achieved with lifestyle modification alone.

Healthcare providers should consider prescribing NuSH-based therapies for patients struggling with overweight and obesity.

Chronic use of NuSH-based therapies may improve weight loss in patients who have not responded optimally or have experienced weight recurrence after metabolic/bariatric surgery.

Consider NuSH-based therapies for patients who have struggled with weight loss after surgery.

The FDA has approved GLP-1R agonists, liraglutide and semaglutide, for the management of obesity.

Practitioners can consider GLP-1R agonists as viable pharmacological options for obesity management.

Tirzepatide consistently showed reductions in HbA1c and benefits with weight loss in clinical trials.

Tirzepatide is effective for improving glycemic control and promoting weight loss in type 2 diabetes patients.

Semaglutid is approved in Germany for the treatment of obesity in adults with a BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with weight-related comorbidities.

Practitioners can consider Semaglutid as a treatment option for eligible patients with obesity.

Weight loss under Semaglutid therapy can be comparable to bariatric surgical intervention.

Semaglutid may be a viable alternative for patients who are not candidates for surgery.

Tirzepatide achieved up to 20.9% weight loss over 72 weeks in non-diabetic obese individuals.

Tirzepatide can be considered an effective option for weight management in non-diabetic obese patients.

GLP-1 receptor agonists are associated with greater reductions in body weight compared to lifestyle interventions and previous medications.

GLP-1 RAs may be a more effective option for weight loss compared to traditional lifestyle changes.

Tirzepatide (TZP) reduces HbA1c levels by −2.1% compared to insulin lispro U100 added to basal insulin.

TZP may be a more effective treatment option for lowering HbA1c in patients with T2D compared to insulin lispro.

Liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) are FDA-approved GLP-1 receptor agonists for weight management.

Practitioners can consider liraglutide and semaglutide as viable options for patients needing weight management.

Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.

Practitioners may consider incretin-based therapies as effective treatment options for improving health outcomes in patients with obesity-related HFpEF.

Semaglutide can be used safely and efficiently in non-diabetic people with excess weight.

Semaglutide may be considered as a treatment option for weight management in non-diabetic patients.

GLP-1 receptor agonists have demonstrated efficacy and safety in treating type 2 diabetes and obesity.

GLP-1 receptor agonists can be considered effective options for managing type 2 diabetes and obesity.

New pharmacologic advances in glucagon-like peptide-1 agonists, such as semaglutide, have shown promising effectiveness for weight management.

Plastic surgeons should consider the role of GLP-1 agonists in managing obesity in surgical patients.

Semaglutide and tirzepatide are effective medication options for obesity management.

Practitioners can consider semaglutide and tirzepatide as viable options for treating obesity.

Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.

Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help manage type 2 diabetes mellitus (T2DM) by controlling blood sugar and promoting weight loss.

GLP-1RAs can be considered as a treatment option for patients with T2DM who need to manage blood sugar and weight.

GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.

Practitioners can consider GLP-1RAs as effective options for managing obesity and glycemic control in patients.